Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.

about

Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.

Item

http://www.wikidata.org/entity/Q54247051

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Efficacy and safety of boosted ...... a-analysis of clinical trials.

@en

Efficacy and safety of boosted ...... a-analysis of clinical trials.

@nl

type

Item

label

Efficacy and safety of boosted ...... a-analysis of clinical trials.

@en

Efficacy and safety of boosted ...... a-analysis of clinical trials.

@nl

prefLabel

Efficacy and safety of boosted ...... a-analysis of clinical trials.

@en

Efficacy and safety of boosted ...... a-analysis of clinical trials.

@nl

P1476

Efficacy and safety of boosted ...... ta-analysis of clinical trials

@en

P2093

A Antinori

http://www.w3.org/2001/XMLSchema#string

A Uglietti

http://www.w3.org/2001/XMLSchema#string

D Mancusi

http://www.w3.org/2001/XMLSchema#string

M Palma

http://www.w3.org/2001/XMLSchema#string

R Termini

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

HIV-1 drug resistance and resistance testing.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Quantitative methods in the review of epidemiologic literature.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

P304

5288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/S41598-018-23375-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adriano Lazzarin

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29588457

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

5869729

http://www.w3.org/2001/XMLSchema#string